Dafydd H. Thomas

Dafydd H. Thomas

Auto-generated profile, based on publicly available information

Dafydd H. Thomas

PMV Pharmaceuticals, Inc, Princeton, New Jersey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. In this study, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing antiproliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild-type p53 program. These compounds demonstrate potent antitumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational phase II clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. Significance: Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

14 November 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MHMarie Christin Hasselluhn
Marie Christin Hasselluhn
ADAmanda R. Decker-Farrell
Amanda R. Decker-Farrell
LVLukas J Vlahos
Lukas J Vlahos
DTDafydd H. Thomas
Dafydd H. Thomas
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
KOKenneth P. Olive
Kenneth P. Olive
The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding from prior work on paracrine communication between malignant PDAC cells and fibroblasts revealed that inhibition of the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor vascularity through unknown mechanisms. Initial efforts to study this phenotype were hindered by difficulties replicating the complex interactions of multiple cell types in vitro. Here we identify a cascade of paracrine signals between multiple cell types that act sequentially to suppress angiogenesis in PDAC. Malignant epithelial cells promote HH signaling in fibroblasts, leading to inhibition of noncanonical WNT signaling in fibroblasts and epithelial cells, thereby limiting VEGFR2-dependent activation of endothelial hypersprouting. This cascade was elucidated using human and murine PDAC explant models, which effectively retain the complex cellular interactions of native tumor tissues.Significance: We present a key mechanism of tumor angiosuppression, a process that sculpts the physiologic, cellular, and metabolic environment of PDAC. We further present a computational and experimental framework for the dissection of complex signaling cascades that propagate among multiple cell types in the tissue environment.This article is featured in Selected Articles from This Issue, p. 201

8 February 2024
Verified
Other
Open access
MHMarie Christin Hasselluhn
Marie Christin Hasselluhn
ADAmanda R. Decker-Farrell
Amanda R. Decker-Farrell
LVLukas J Vlahos
Lukas J Vlahos
DTDafydd H. Thomas
Dafydd H. Thomas
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
KOKenneth P. Olive
Kenneth P. Olive
Endothelial network.Regulatory network for PDAC-associated endothelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

8 February 2024
Verified
Other
Open access
MHMarie Christin Hasselluhn
Marie Christin Hasselluhn
ADAmanda R. Decker-Farrell
Amanda R. Decker-Farrell
LVLukas J Vlahos
Lukas J Vlahos
DTDafydd H. Thomas
Dafydd H. Thomas
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
KOKenneth P. Olive
Kenneth P. Olive
Lymphoid network.Regulatory network for PDAC-associated lymphoid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

8 February 2024
Verified
Other
Open access
MHMarie Christin Hasselluhn
Marie Christin Hasselluhn
ADAmanda R. Decker-Farrell
Amanda R. Decker-Farrell
LVLukas J Vlahos
Lukas J Vlahos
DTDafydd H. Thomas
Dafydd H. Thomas
ACAlvaro Curiel-Garcia
Alvaro Curiel-Garcia
KOKenneth P. Olive
Kenneth P. Olive
Epithelial network.Regulatory network for PDAC-associated epithelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).